Dovato, which combines the integrase strand transfer inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitor lamivudine, was approved to treat HIV-1 infection in adolescents 12 years and older, making it the first oral, two-drug, single-tablet regimen available for this patient population, according to ViiV
2016;1640(Pt A):5776
Moreover, the gut dysbiosis can induce chronic low-grade inflammation, and the inflammatory environment increases the ROS level, which also establishes the vicious cycle of OS (44), shown as Figure 2d
However, results vary based on the patients age, diagnosis, overall health, lifestyle, and the severity of their condition
Limitation: small sample (n=7), combination protocol
The potential for peptides to one day become approved treatments for a host of debilitating injuries and conditions is immense